Title:

Predicting In-hospital Mortality Using Elixhauser Comorbidity in Patients Underwent Single and Multiple Coronary Artery Bypass Surgery

Author: Renxi Li, BS[1]

1.The George Washington University School of Medicine and Health Sciences

Short Title: Predict Coronary Bypass In-hospital Mortality

Correspondence information: Renxi Li, 2300 I St NW, Washington, DC 20052;

renxili@gwu.edu

Word Count: 4080

Abstract

Background: Coronary Artery Bypass Graft (CABG) surgery is a high-risk surgery (mortality rate between 2-4 percent) performed in patients with ischemic heart disease (IHD). Cardiovascular diseases are strongly associated with comorbidities. This study aimed to assess the prediction of in-hospital mortality by comorbidities in patients who underwent single, double, triple, or quadruple and more CABG.

Methods:

The National Inpatient Sample (NIS) database was used to extract patients who received 1, 2, 3, or 4+ CABG between the last quarter of 2015 and 2020. Best-fit model by logistic regressions was used to predict in-hospital mortality by Elixhauser Comorbidity Index (ECI). Moreover, age was adjusted in ECI prediction.

Results:

In-hospital mortality was best predicted by ECI in patients who underwent 3 CABG (*c*-statistic = 0.6325, 95% CI = 0.6151-0.6499), followed by 4+ CABG (*c*-statistic = 0.6308, 95% CI = 0.5997-0.6620), 1 CABG (*c*-statistic = 0.6194, 95% CI = 0.6108-0.6281), and 2 CABG (*c*-statistic = 0.6193, 95% CI = 0.6069-0.6317). After adjusting for age, ECI adequately predicted in-hospital mortality in 4+ CABG (*c*-statistic = 0.7196, 95% CI = 0.6916-0.7477) and 3 CABG (*c*-statistic = 0.6937, 95% CI = 0.6774-0.7101). The predictive power for age-adjusted ECI was comparable in 1 CABG (*c*-statistic = 0.6674, 95% CI = 0.6594-0.6755) and 2 CABG (*c*-statistic = 0.6664, 95% CI = 0.6549-0.6780).

Conclusions:

This study showed that ECI alone was a moderate (*c*-statistic 0.6-0.7) predictor of in-hospital mortality in all CABG. Age-adjusted ECI could effectively predict in-hospital mortality, especially in patients who underwent 3 and 4+ CABG.

Keywords:

Coronary Artery Bypass Graft, Elixhauser Comorbidity, In-hospital Mortality, Mortality Prediction

Non-standard Abbreviations and Acronyms

AUC, area under curve;

CABG, Coronary Artery Bypass Graft;

CI, confidence interval;

ECI, Elixhauser Comorbidity Index;

ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification;

ICD-10-PCS, International Classification of Diseases, Tenth Revision, Procedure Coding System;

IHD, ischemic heart disease;

NIS, National (Nationwide) Inpatient Sample;

ROC, receiver operating characteristic.

Introduction

Coronary Artery Bypass Graft (CABG) surgery is a frequently performed cardiac surgery procedure to relieve symptoms and reduce mortality risk in patients suffering from ischemic heart disease (IHD) [1–3]. CABG is a high-risk surgery with a crude in-hospital mortality rate between 2-4 percent compared to 0.7% of all surgeries [1,4–7]. When there is more than one blockage in the coronary arteries, multiple bypasses are needed. Multiple bypasses have been shown to have better long-term outcomes in low-risk patients while high-risk patients have worse peri-operative outcomes [8]. However, in-hospital mortality differences in single and multiple bypasses have not been assessed. Age has been well-established as an independent predictor for morality in CABG; increased age is associated with increased risk for complications post-CABG [9–14]. Thus, age, as a high-risk factor, needs to be accounted for when examining the in-hospital mortality difference in single and multiple CABG.

To adjust for risk when evaluating clinical outcomes, it is often necessary to take into account comorbidities [15,16]. The Elixhauser Comorbidity measure was created to identify a broad range of comorbidities using ICD codes in large-scale administrative data [17]. In the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) system, there are 38 comorbidities identified [18]. Many studies have demonstrated the effectiveness of the Elixhauser Comorbidity measure in predicting the risk of in-hospital mortality [19–21].

More recently, the Elixhauser Comorbidity measure has been developed into the Elixhauser Comorbidity Index (ECI), which is a weighted scoring system that predicts in-hospital mortality [22]. During the validation phase of its development, the Elixhauser Comorbidity Index (ECI) demonstrated strong predictive ability (*c*-statistic = 0.777, 95% CI = 0.776-0.778) for in-hospital mortality across all subjects [22]. Although the ECI has been validated in several

disease categories, including several cardiac diseases with high mortality rates such as acute myocardial infarction and non-hypertensive congestive heart failure, it has not been specifically evaluated for predicting in-hospital mortality in patients who underwent CABG procedure [22].

This study aimed to assess the prediction of in-hospital mortality by ECI in patients who underwent single, double, triple, or quadruple and more CABG. This study used the National (Nationwide) Inpatient Sample (NIS) database, which is the largest in-patient database that accounts for 20% of discharges in the United States [23]. In addition, age was adjusted when examining the ECI prediction of in-hospital mortality in patients who underwent CABG.

Materials and Methods

The NIS database was used to extract patients who received 1, 2, 3, or 4+ CABG using the International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) between the last quarter of 2015 and 2020. The ICD-10-PCS codes to extract cases were listed in Supplement Table 1. Patient age, the record of in-hospital mortality, and ICD-10-CM were extracted. Elixhauser Comorbidity Software was used to identify 38 Elixhauser Comorbidity to calculate ECI [24]. The weights for the Elixhauser Comorbidities in ECI calculation were listed in Supplement Table 1.

Best-fit model by logistic regressions was used to predict in-hospital mortality by ECI in patients who underwent 1, 2, 3, and 4+ CABG, respectively. Multivariable logistic regressions adjusting for age were performed to assess in-hospital mortality prediction by ECI in a best-fit prediction model in 1, 2, 3, and 4+ CABG, respectively. The receiver operating characteristic (ROC) for each best-fit model was plotted and the area under the ROC curve (AUC) was estimated including a 95% confidence interval (CI).

Each best-fit model's ability to discriminate in-hospital mortality was characterized by *c*-statistic. When *c*-statistic = 0.5, the model does not predict better than chance, and when *c*-statistic = 1, the model accurately predicts all occurrences of in-hospital death. A *c*-statistic between 0.6 and 0,7 has moderate predictor power. The threshold for *c*-statistic is 0.7 for adequate predictor power.

All analyses were performed by SAS (version 9.4). The study was retrospective and was based on the open NIS database. Thus, this study was IRB-exempted. The author had full access to all the data in the study and takes responsibility for its integrity and the data analysis.

Results

There were 190524, 83725, 48147, and 13540 patients who underwent 1, 2, 3, and 4+ CABG, respectively, between the last quarter of 2015 and 2020 from NIS. The characteristics of the patients were summarized in Table 1. Patients who underwent 1, 2, 3, and 4+ CABG had a mean age of 66.18 ± 10.08, 66.47 ± 9.95, 66.15 ± 9.74, and 65.63 ± 9.76, respectively. The in-hospital mortality was highest in 2 CABG (1970/83725, 2.35%), followed by 4+ CABG (309/13540, 2.28%), 1 CABG (4302/190524, 2.26%), and 3 CABG (1017/48147, 2.11%). Patients who underwent 1, 2, 3, and 4+ CABG had an average ECI of -2.02 ± 5.34 (min = -30, max = 39), -2.02 ± 5.41 (min = -27, max = 35), -1.99 ± 5.24 (min = -28, max = 32), and -2.01 ± 5.18 (min = -25, max = 30), respectively.

A summary of the identified Elixhauser Comorbidities in patients who underwent 1, 2, 3, and 4+ CABG was presented in Table 2. The most common Elixhauser Comorbidities were uncomplicated hypertension (1 CABG, 50.68%; 2 CABG, 50.59%; 3 CABG, 51.01%; 4+ CABG, 50.30%), complicated hypertension (1 CABG, 36.67%; 2 CABG, 37.35%; 3 CABG,

36.90%; 4+ CABG, 36.90%), diabetes with chronic complications (1 CABG, 31.42%; 2 CABG, 32.64%; 3 CABG, 32.65%; 4+ CABG, 32.65%), obesity (1 CABG, 28.55%; 2 CABG, 28.82%; 3 CABG, 27.94%; 4+ CABG, 27.94%), chronic pulmonary disease (1 CABG, 21.75%; 2 CABG, 21.98%; 3 CABG, 20.89%; 4+ CABG, 20.89%), diabetes without chronic complications (1 CABG, 16.49%; 2 CABG, 16.37%; 3 CABG, 17.69%; 4+ CABG, 17.69%), peripheral vascular disease (1 CABG, 15.06%; 2 CABG, 15.21%; 3 CABG, 14.27%; 4+ CABG, 14.27%), hypothyroidism (1 CABG, 11.16%; 2 CABG, 11.34%; 3 CABG, 10.55%; 4+ CABG, 10.55%), depression (1 CABG, 8.73%; 2 CABG, 8.83%; 3 CABG, 8.19%; 4+ CABG, 8.19%), alcohol abuse (1 CABG, 3.36%; 2 CABG, 3.46%; 3 CABG, 3.43%; 4+ CABG, 3.43%), autoimmune conditions (1 CABG, 2.58%; 2 CABG, 2.56%; 3 CABG, 2.33%; 4+ CABG, 2.33%), severe renal failure (1 CABG, 2.37%; 2 CABG, 2.45%; 3 CABG, 2.28%; 4+ CABG, 2.28%), cerebrovascular disease (1 CABG, 1.97%; 2 CABG, 2.07%; 3 CABG, 2.02%; 4+ CABG, 2.02%), drug abuse (1 CABG, 1.70%; 2 CABG, 1.62%; 3 CABG, 1.67%; 4+ CABG, 1.67%), paralysis (1 CABG, 1.41%; 2 CABG, 1.50%; 3 CABG, 1.45%; 4+ CABG, 1.45%), malignant solid tumor without metastasis(1 CABG, 1.32%; 2 CABG, 1.37%; 3 CABG, 1.22%; 4+ CABG, 1.22%), valvular disease (1 CABG, 1.20%; 2 CABG, 0.86%; 3 CABG, 0.56%; 4+ CABG, 0.56%), dementia (1 CABG, 1.10%; 2 CABG, 1.17%; 3 CABG, 1.13%; 4+ CABG, 1.13%), other thyroid disorders (1 CABG, 1.05%; 2 CABG, 1.05%; 3 CABG, 0.96%; 4+ CABG, 0.96%), leukemia (1 CABG, 0.42%; 2 CABG, 0.41%; 3 CABG, 0.48%; 4+ CABG, 0.48%), lymphoma (1 CABG, 0.37%; 2 CABG, 0.37%; 3 CABG, 0.34%; 4+ CABG, 0.34%), acquired immune deficiency syndrome (1 CABG, 0.36%; 2 CABG, 0.36%; 3 CABG, 0.34%; 4+ CABG, 0.34%), metastatic cancer (1 CABG, 0.23%; 2 CABG, 0.26%; 3 CABG, 0.20%; 4+ CABG, 0.20%), moderate to

severe liver disease (1 CABG, 0.09%; 2 CABG, 0.09%; 3 CABG, 0.06%; 4+ CABG, 0.06%), heart failure (1 CABG, 0.08%; 2 CABG, 0.09%; 3 CABG, 0.08%; 4+ CABG, 0.08%), in situ solid tumor without metastasis (1 CABG, 0.02%; 2 CABG, 0.02%; 3 CABG, 0.02%; 4+ CABG, 0.02%). In neither CABG group, there were no cases of anemias due to other nutritional deficiencies, chronic blood loss anemia (iron deficiency), coagulopathy, mild liver disease, neurological disorders affecting movement, other neurological disorders, seizures and epilepsy, psychoses, pulmonary circulation disease, moderate renal failure, peptic ulcer disease x bleeding, or weight loss.

A summary of ECI prediction of in-hospital mortality was shown in Figure 1 and summarized in Table 3. While all of the *c*-statistics did not reach adequacy (*c*-statistic > 0.7), in-hospital mortality was best predicted by ECI in patients who underwent 3 CABG (*c*-statistic = 0.6325, 95% CI = 0.6151-0.6499), followed by 4+ CABG (*c*-statistic = 0.6308, 95% CI = 0.5997-0.6620). The predictive power of ECI in patients who underwent 1 CABG (*c*-statistic = 0.6194, 95% CI = 0.6108-0.6281) and 2 CABG (*c*-statistic = 0.6193, 95% CI = 0.6069-0.6317) were comparable.

The age-adjusted ECI prediction of in-hospital mortality was also shown in Figure 2 and summarized in Table 3. The predictive power of ECI in all groups of patients was improved by the adjustment of age. The prediction of in-hospital mortality in 4+ CABG patients was adequate (*c*-statistic = 0.7196, 95% CI = 0.6916-0.7477), and that in 3 CABG patients was approaching adequacy (*c*-statistic = 0.6937, 95% CI = 0.6774-0.7101). The predictive power of ECI in patients who underwent 1 CABG (*c*-statistic = 0.6674, 95% CI = 0.6594-0.6755) and 2 CABG (*c*-statistic = 0.6664, 95% CI = 0.6549-0.6780) were still comparable after adjusting for age.

Discussion

This study examined the prediction of in-hospital mortality by ECI in patients who underwent 1, 2, 3, and 4+ CABG in NIS data from the last quarter of 2015 to 2020. In addition, age, as a strong risk factor for in-hospital mortality in CABG, was adjusted in the predictive model by ECI.

ECI was found to be a moderate (*c*-statistic > 0.6) predictor for in-hospital mortality in all groups of CABG patients. ECI slightly better discriminated in-hospital mortality in 3 and 4+ (*c*-statistic = 0.6325 and 0.6308, respectively) than 1 and 2 (*c*-statistic = 0.6194 and 0.6193, respectively) CABG patients. In other words, in patients who underwent a high number (>2) of coronary artery bypasses, sicker patients (with more comorbidities) were more associated with mortality. This is clinically justifiable since cardiovascular disease is strongly associated with comorbidities, such as diabetes, hypertension, and dyslipidemia [25]. Patients with worse overall health conditions are more likely to develop more advanced cardiovascular diseases such as multiple coronary artery blockages that have worse prognoses after the surgery. As a result, comorbidities and mortality are more likely to have an association in patients who undergo multiple coronary artery bypasses.

Although the predictive power of ECI was improved after adjusting for age, the extent of improvement was different depending on the number of coronary bypasses. While the *c*-statistic increased by 0.5-0.6 in patients who underwent 1, 2, and 3 CABG, the *c*-statistic increased by about 0.9 in 4+ CABG patients. The age-adjusted ECI was found to adequately predict (*c*-statistic = 0.7196) in-hospital mortality in 4+ CABG patients, meaning age is a greater risk factor for mortality in these patients. In 3 CABG patients, age-adjusted ECI could also adequately discriminate (*c*-statistic = 0.6937) in-hospital mortality. Thus, age-adjusted ECI is especially

effective to predict in-hospital mortality in patients underwent a high number (>2) of coronary artery bypasses.

There were several limitations of this study. First, all in-hospital mortality examined in this study did not have any follow-up in NIS. It was also argued that the 30-day post-surgery period should be monitored for early perioperative outcomes [26]. Secondly, The Elixhauser Comorbidities were documented in a binary format, indicating whether they were present or absent. This allowed for greater diversity among patients with the same comorbidity, as they may have varying degrees or stages of the disease. In addition, many risk factors in CABG, such as ejection fraction, previous open heart operations, and serum creatine, that can adjust ECI prediction are not recorded in NIS [27,28]. ECI should be used together with other relevant clinical information, such as specific diagnosis, past medical history, and lab values to accurately assess mortality risk.

Nevertheless, this study showed that age-adjusted ECI can effectively predict in-hospital mortality, especially in patients who underwent 3 and 4+ CABG. Future studies can examine the effect of graft properties, such as venous, arterial, or hybrid grafting, and bypass procedures, such as off-pump versus minimally invasive, on adjusting the prediction of in-hospital mortality by ECI in CABG patients. Furthermore, the weight of the comorbidities in ECI as shown in Table 2 was derived in the larger population. For example, valvular disease was given a weight of 0 in ECI, but the presence of valvular disease might be a predisposition factor for mortality in CABG and thus should be given a positive weight. Future studies can further optimize the weight of these comorbidities in patients who underwent CABG to derive a CABG-specific comorbidity index score.

Acknowledgments: Renxi Li participated in all aspects of the study.

Sources of Funding: None.

Disclosures: The author declares no conflicts of interest.

Supplemental Material: Supplementary Table 1.

Reference

1. Adelborg K, Horváth-Puhó E, Schmidt M, Munch T, Pedersen L, Nielsen PH, Bøtker HE, Toft Sørensen H. Thirty-Year Mortality After Coronary Artery Bypass Graft Surgery. *Circulation: Cardiovascular Quality and Outcomes*. 2017;10:e002708.

2. Konstantinov IE. The First Coronary Artery Bypass Operation and Forgotten Pioneers. *The Annals of Thoracic Surgery*. 1997;64:1522–1523.

3. Weiss AJ, Elixhauser A, Andrews RM. Characteristics of Operating Room Procedures in U.S. Hospitals, 2011. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006. Available at http://www.ncbi.nlm.nih.gov/books/NBK195245/. Accessed March 31, 2023.

4. D'Agostino RS, Jacobs JP, Badhwar V, Fernandez FG, Paone G, Wormuth DW, Shahian DM. The Society of Thoracic Surgeons Adult Cardiac Surgery Database: 2018 Update on Outcomes and Quality. *Ann Thorac Surg*. 2018;105:15–23.

5. Heeney A, Hand F, Bates J, Mc Cormack O, Mealy K. Surgical mortality - an analysis of all deaths within a general surgical department. *Surgeon*. 2014;12:121–128.

6. Rathore SS, Epstein AJ, Volpp KGM, Krumholz HM. Hospital Coronary Artery Bypass Graft Surgery Volume and Patient Mortality, 1998–2000. *Ann Surg*. 2004;239:110–117.

7. Sonny A, Joseph L. Improving CABG Mortality Further. *Journal of the American College of Cardiology*. 2021;78:123–125.

8. Gaudino M, Samadashvili Z, Hameed I, Chikwe J, Girardi LN, Hannan EL. Differences in Long-term Outcomes After Coronary Artery Bypass Grafting Using Single vs Multiple Arterial Grafts and the Association With Sex. *JAMA Cardiology*. 2021;6:401–409.

9. Hannan EL, Burke J. Effect of age on mortality in coronary artery bypass surgery in New York, 1991-1992. *Am Heart J*. 1994;128:1184–1191.

10. Hansen LS, Hjortdal VE, Andreasen JJ, Mortensen PE, Jakobsen C-J. 30-day mortality after coronary artery bypass grafting and valve surgery has greatly improved over the last decade, but the 1-year mortality remains constant. *Ann Card Anaesth*. 2015;18:138–142.

11. Lemaire A, Soto C, Salgueiro L, Ikegami H, Russo MJ, Lee LY. The impact of age on outcomes of coronary artery bypass grafting. *Journal of Cardiothoracic Surgery*. 2020;15:158.

12. Peterson ED, Cowper PA, Jollis JG, Bebchuk JD, DeLong ER, Muhlbaier LH, Mark DB, Pryor DB. Outcomes of Coronary Artery Bypass Graft Surgery in 24 461 Patients Aged 80 Years or Older. *Circulation*. 1995;92:85–91.

13. Ribera A, Ferreira-González I, Cascant P, Pons JM, Permanyer-Miralda G. Evaluation of Risk-Adjusted Hospital Mortality After Coronary Artery Bypass Graft Surgery in the Catalan Public Healthcare System. Influence of Hospital Management Type (ARCA Study). *Rev Esp Cardiol*. 2006;59:431–440.

14. Thorsteinsson K, Fonager K, Mérie C, Gislason G, Køber L, Torp-Pedersen C, Mortensen RN, Andreasen JJ. Age-dependent trends in postoperative mortality and preoperative

comorbidity in isolated coronary artery bypass surgery: a nationwide study†. *European Journal of Cardio-Thoracic Surgery*. 2016;49:391–397.

15. Harrison C, Britt H, Miller G, Henderson J. Examining different measures of multimorbidity, using a large prospective cross-sectional study in Australian general practice. *BMJ Open*. 2014;4:e004694.

16. Pefoyo AJK, Bronskill SE, Gruneir A, Calzavara A, Thavorn K, Petrosyan Y, Maxwell CJ, Bai Y, Wodchis WP. The increasing burden and complexity of multimorbidity. *BMC Public Health*. 2015;15:415.

17. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. *Med Care*. 1998;36:8–27.

18. Elixhauser Comorbidity Software Refined for ICD-10-CM. Available at https://hcup-us.ahrq.gov/toolssoftware/comorbidityicd10/comorbidity_icd10.jsp. Accessed March 25, 2023.

19. Menendez ME, Neuhaus V, van Dijk CN, Ring D. The Elixhauser Comorbidity Method Outperforms the Charlson Index in Predicting Inpatient Death After Orthopaedic Surgery. *Clin Orthop Relat Res*. 2014;472:2878–2886.

20. Metcalfe D, Masters J, Delmestri A, Judge A, Perry D, Zogg C, Gabbe B, Costa M. Coding algorithms for defining Charlson and Elixhauser co-morbidities in Read-coded databases. *BMC Med Res Methodol*. 2019;19:115.

21. Stukenborg GJ, Wagner DP, Connors AF. Comparison of the performance of two comorbidity measures, with and without information from prior hospitalizations. *Med Care*. 2001;39:727–739.

22. Moore BJ, White S, Washington R, Coenen N, Elixhauser A. Identifying Increased Risk of Readmission and In-hospital Mortality Using Hospital Administrative Data: The AHRQ Elixhauser Comorbidity Index. *Medical Care*. 2017;55:698.

23. NIS Database Documentation. Available at https://hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp. Accessed March 25, 2023.

24. Elixhauser Comorbidity Software Refined for ICD-10-CM. Available at https://hcup-us.ahrq.gov/toolssoftware/comorbidityicd10/comorbidity_icd10.jsp. Accessed March 25, 2023.

25. Kendir C, van den Akker M, Vos R, Metsemakers J. Cardiovascular disease patients have increased risk for comorbidity: A cross-sectional study in the Netherlands. *Eur J Gen Pract*. 2017;24:45–50.

26. Volpp KG, Rosen AK, Rosenbaum PR, Romano PS, Even-Shoshan O, Wang Y, Bellini L, Behringer T, Silber JH. Mortality among hospitalized Medicare beneficiaries in the first 2 years following ACGME resident duty hour reform. *JAMA*. 2007;298:975–983.

27. dos Santos CA, de Oliveira MAB, Brandi AC, Botelho PHH, Brandi J de CM, dos Santos MA, de Godoy MF, Braile DM. Risk factors for mortality of patients undergoing coronary artery bypass graft surgery. *Rev Bras Cir Cardiovasc*. 2014;29:513–520.

28. Hannan EL, Wu C, Bennett EV, Carlson RE, Culliford AT, Gold JP, Higgins RSD, Isom OW, Smith CR, Jones RH. Risk Stratification of In-Hospital Mortality for Coronary Artery Bypass Graft Surgery. *Journal of the American College of Cardiology*. 2006;47:661–668.

Table 1. Characteristics of patients who underwent 1, 2, 3, or 4+ Coronary Artery Bypass Surgery (CABG) from the last quarter of 2015 to 2020 were identified in the National (Nationwide) Inpatient Sample (NIS) database.
Abbreviations: CABG, Coronary Artery Bypass Surgery; ECI, Elixhauser Comorbidities Index; SD, standard deviation.

	Total Case	**Age, mean ± SD**	**In-hospital Mortality, n (%)**	**ECI, mean ± SD (min, max)**
1 CABG	190524	66.18 ± 10.08	4302 (2.26%)	-2.02 ± 5.34 (-30, 39)
2 CABG	83725	66.47 ± 9.95	1970 (2.35%)	-2.02 ± 5.41 (-27, 35)
3 CABG	48147	66.15 ± 9.74	1017 (2.11%)	-1.99 ± 5.24 (-28, 32)
4+ CABG	13540	65.63 ± 9.76	309 (2.28%)	-2.01 ± 5.18 (-25, 30)

Table 2. Elixhauser Comorbidities identified by ICD-10 Clinical Modification (ICD-10-CM) to derive the Elixhauser Comorbidities Index (ECI) in patients who underwent 1, 2, 3, or 4+ Coronary Artery Bypass Surgery (CABG) from the last quarter of 2015 to 2020 in National (Nationwide) Inpatient Sample (NIS) database.

Elixhauser Comorbidities	1 CABG, n (%)	2 CABG, n (%)	3 CABG, n (%)	4+ CABG, n (%)	Weight
Acquired immune deficiency syndrome	690 (0.36%)	304 (0.36%)	165 (0.34%)	40 (0.30%)	-4
Alcohol abuse	6398 (3.36%)	2901 (3.46%)	1650 (3.43%)	423 (3.12%)	-1
Anemias due to other nutritional deficiencies	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	-3
Autoimmune conditions	4917 (2.58%)	2142 (2.56%)	1120 (2.33%)	295 (2.18%)	0
Chronic blood loss anemia (iron deficiency)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	-4
Lymphoma	704 (0.37%)	307 (0.37%)	162 (0.34%)	54 (0.40%)	9
Leukemia	809 (0.42%)	347 (0.41%)	232 (0.48%)	43 (0.32%)	5
Metastatic cancer	429 (0.23%)	220 (0.26%)	95 (0.20%)	26 (0.19%)	22
Solid tumor without metastasis, in situ	41 (0.02%)	15 (0.02%)	12 (0.02%)	5 (0.04%)	0
Solid tumor without metastasis, malignant	2511 (1.32%)	1147 (1.37%)	585 (1.22%)	167 (1.23%)	10
Cerebrovascular disease	3760 (1.97%)	1732 (2.07%)	974 (2.02%)	271 (2.00%)	5
Heart failure	150 (0.08%)	75 (0.09%)	39 (0.08%)	16 (0.12%)	14
Coagulopathy	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	14
Dementia	2089 (1.10%)	982 (1.17%)	542 (1.13%)	125 (0.92%)	5
Depression	16628 (8.73%)	7389 (8.83%)	3943 (8.19%)	989 (7.30%)	-8
Diabetes without chronic complications	31412 (16.49%)	13704 (16.37%)	8519 (17.69%)	2514 (18.57%)	-2
Diabetes with chronic complications	59869 (31.42%)	27330 (32.64%)	15719 (32.65%)	4439 (32.78%)	0
Drug abuse	3238 (1.70%)	1360 (1.62%)	802 (1.67%)	265 (1.96%)	-7
Hypertension, complicated	69861 (36.67%)	31269 (37.35%)	17765 (36.90%)	4980 (36.78%)	1

Hypertension, uncomplicated	96561 (50.68%)	42360 (50.59%)	24562 (51.01%)	6811 (50.30%)	0
Liver disease, mild	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2
Liver disease, moderate to severe	165 (0.09%)	74 (0.09%)	27 (0.06%)	14 (0.10%)	16
Chronic pulmonary disease	41430 (21.75%)	18403 (21.98%)	10057 (20.89%)	2555 (18.87%)	2
Neurological disorders affecting movement	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	-1
Other neurological disorders	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	22
Seizures and epilepsy	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2
Obesity	54403 (28.55%)	24126 (28.82%)	13452 (27.94%)	3762 (27.78%)	-7
Paralysis	2681 (1.41%)	1258 (1.50%)	696 (1.45%)	191 (1.41%)	4
Peripheral vascular disease	28694 (15.06%)	12731 (15.21%)	6872 (14.27%)	1710 (12.63%)	3
Psychoses	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	-9
Pulmonary circulation disease	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	4
Renal failure, moderate	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	3
Renal failure, severe	4511 (2.37%)	2052 (2.45%)	1096 (2.28%)	294 (2.17%)	7
Hypothyroidism	21266 (11.16%)	9492 (11.34%)	5081 (10.55%)	1350 (9.97%)	-3
Other thyroid disorders	2000 (1.05%)	882 (1.05%)	460 (0.96%)	118 (0.87%)	-8
Peptic ulcer disease x bleeding	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0
Valvular disease	2289 (1.20%)	721 (0.86%)	271 (0.56%)	57 (0.42%)	0
Weight loss	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	13

Table 3. In-hospital mortality discrimination by Elixhauser Comorbidities Index (ECI), as well as ECI, adjusted for age in patients who underwent 1, 2, 3, or 4+ Coronary Artery Bypass Surgery (CABG) from the last quarter of 2015 to 2020 identified in National (Nationwide) Inpatient Sample (NIS) database.
Abbreviations: CABG, Coronary Artery Bypass Surgery; ECI, Elixhauser Comorbidities Index.

	C-Statistic	Lower 95% CI	Upper 95% CI
ECI			
1 CABG	0.6194	0.6108	0.6281
2 CABG	0.6193	0.6069	0.6317
3 CABG	0.6325	0.6151	0.6499
4+ CABG	0.6308	0.5997	0.6620
ECI adjusted for age			
1 CABG	0.6674	0.6594	0.6755
2 CABG	0.6664	0.6549	0.6780
3 CABG	0.6937	0.6774	0.7101
4+ CABG	0.7196	0.6916	0.7477



Figure 1. Receiver operating characteristic (ROC) curves for logistic regression models predicting in-hospital mortality by Elixhauser Comorbidities Index (ECI) in patients who underwent 1, 2, 3, or 4+ Coronary Artery Bypass Surgery (CABG) from the last quarter of 2015 to 2020 identified in National (Nationwide) Inpatient Sample (NIS) database. A straight diagonal line shows the null model (AUC 0.500).



Figure 2. Receiver operating characteristic (ROC) curves for multivariable logistic regression models predicting in-hospital mortality by Elixhauser Comorbidities Index (ECI) after adjusting for age in patients who underwent 1, 2, 3, or 4+ Coronary Artery Bypass Surgery (CABG) from the last quarter of 2015 to 2020 identified in National (Nationwide) Inpatient Sample (NIS) database. A straight diagonal line shows the null model (AUC 0.500).